|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Laurent Levy Ph.D.||Co-Founder, President of the Executive Board & CEO||635,14k||S.O.||1973|
|Mr. Bart Van Rhijn||CFO & Member of Executive Board||563,44k||S.O.||1973|
|Ms. Anne-Juliette Hermant M.A.||Chief People Officer & Member of Executive Board||309,75k||S.O.||1974|
|Mr. Earl J. Bergey Ph.d.||Co-Founder||S.O.||S.O.||1955|
|Mr. Alain Dostie||Chief Operating Officer||S.O.||S.O.||S.O.|
|Ms. Kathryn M. McNeil||Senior Vice President of Investor Relations||S.O.||S.O.||1975|
|Mr. Brandon Owens||VP of Strategic Marketing & Corporate Communication||S.O.||S.O.||S.O.|
|Mr. Patrick Tricoli M.B.A., Pharm.D.||Global Head of Business Development||S.O.||S.O.||S.O.|
|Ms. Margaret Galluzzi||VP & Global Head of Clinical Operations||S.O.||S.O.||S.O.|
|Mr. Ventzislav Vassilev M.D.||VP & Global Head of Safety Vigilance||S.O.||S.O.||S.O.|
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
L’ISS Governance QualityScore de Nanobiotix S.A. en date du 1 novembre 2023 est 9. Les scores principaux sont Audit : 9; Société : 7; Droits des actionnaires : 7; Compensation : 10.